One of the world’s hottest spots for raising capital is back in business. Ten months after halting initial public offerings, or flotations, on Chinese bourses, the government has cleared the way for Guilin Sanjin Pharmaceutical, a maker of traditional Chinese medicines, to list on the Shenzhen exchange. The company plans to raise $133 million with the IPO, which offered subscriptions to retail investors Monday
